GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » 3SBio Inc (HKSE:01530) » Definitions » EV-to-FCF

3SBio (HKSE:01530) EV-to-FCF : 9.99 (As of May. 05, 2024)


View and export this data going back to 2015. Start your Free Trial

What is 3SBio EV-to-FCF?

EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, 3SBio's Enterprise Value is HK$15,064 Mil. 3SBio's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2023 was HK$1,508 Mil. Therefore, 3SBio's EV-to-FCF for today is 9.99.

The historical rank and industry rank for 3SBio's EV-to-FCF or its related term are showing as below:

HKSE:01530' s EV-to-FCF Range Over the Past 10 Years
Min: 8.99   Med: 39.81   Max: 72.93
Current: 9.99

During the past 10 years, the highest EV-to-FCF of 3SBio was 72.93. The lowest was 8.99. And the median was 39.81.

HKSE:01530's EV-to-FCF is ranked worse than
55.1% of 392 companies
in the Biotechnology industry
Industry Median: 4.57 vs HKSE:01530: 9.99

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-05-05), 3SBio's stock price is HK$6.80. 3SBio's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was HK$0.679. Therefore, 3SBio's PE Ratio for today is 10.01.


3SBio EV-to-FCF Historical Data

The historical data trend for 3SBio's EV-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

3SBio EV-to-FCF Chart

3SBio Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only 17.16 44.65 31.78 15.59 12.92

3SBio Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
EV-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 31.78 - 15.59 - 12.92

Competitive Comparison of 3SBio's EV-to-FCF

For the Biotechnology subindustry, 3SBio's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


3SBio's EV-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, 3SBio's EV-to-FCF distribution charts can be found below:

* The bar in red indicates where 3SBio's EV-to-FCF falls into.



3SBio EV-to-FCF Calculation

3SBio's EV-to-FCF for today is calculated as:

EV-to-FCF=Enterprise Value (Today)/Free Cash Flow (TTM)
=15064.256/1507.798
=9.99

3SBio's current Enterprise Value is HK$15,064 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. 3SBio's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2023 was HK$1,508 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


3SBio  (HKSE:01530) EV-to-FCF Explanation

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

3SBio's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=6.80/0.679
=10.01

3SBio's share price for today is HK$6.80.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. 3SBio's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was HK$0.679.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.


3SBio EV-to-FCF Related Terms

Thank you for viewing the detailed overview of 3SBio's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


3SBio (HKSE:01530) Business Description

Traded in Other Exchanges
Address
No. 3 A1, Road 10, Shenyang Economy and Technology Development Zone, Shenyang, CHN, 110027
3SBio Inc, or 3SBio, is one of the largest and most established biotech drugmakers in China. In 2021, it reported revenue of CNY 6.3 billion. Approximately 90% of its revenue is derived from four core drugs: TPIAO (rhTPO), Yisaipu (biosimilar of etanercept, a TNF-alpha inhibitor), rhEPO, and Mandi (minoxidil). With the exception of minoxidil, an over-the-counter drug, the others are all older generation biologics. Most of the pipeline candidates are "me-too" drugs and in general are still at an early stage.

3SBio (HKSE:01530) Headlines

No Headlines